Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
Abstract Baseline IL-6 levels have been found to be non-predictive of subsequent outcomes following tocilizumab treatment, highlighting the need for more reliable predictive markers. To address this, a retrospective analysis was conducted on the clinical profiles, diagnostic tests, and follow-up pro...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-81028-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216314815119360 |
|---|---|
| author | Panpan Liang Yan Li Li’e Meng Yuting Li Hailing Mai Tao Li Jiarui Ma Junhui Ma Jing Wang Bing Zhuan Wei Zhou |
| author_facet | Panpan Liang Yan Li Li’e Meng Yuting Li Hailing Mai Tao Li Jiarui Ma Junhui Ma Jing Wang Bing Zhuan Wei Zhou |
| author_sort | Panpan Liang |
| collection | DOAJ |
| description | Abstract Baseline IL-6 levels have been found to be non-predictive of subsequent outcomes following tocilizumab treatment, highlighting the need for more reliable predictive markers. To address this, a retrospective analysis was conducted on the clinical profiles, diagnostic tests, and follow-up prognoses of 60 patients with severe or critical COVID-19, all of whom were identified as experiencing a cytokine storm and subsequently received tocilizumab treatment. Among the patients, the overall survival rate during follow-up was 80%, with further analysis revealing that advanced age was an independent risk factor for adverse outcomes. Following tocilizumab administration, a statistically significant increase in IL-6 and D-dimer levels was observed, while markers such as C-reactive protein (CRP), procalcitonin (PCT), and fibrinogen demonstrated reductions compared to pre-treatment values. Specifically, IL-6 levels initially surged briefly after tocilizumab intervention before gradually diminishing. To assess the prognostic utility of IL-6, the Receiver Operating Characteristic (ROC) curve was employed, which yielded an area under the curve (AUC) of 0.812, indicating strong predictive capability, with a sensitivity of 100% and a specificity of 53.49%. The optimal cut-off value for IL-6 was identified at 147.79 pg/mL. In conclusion, IL-6 levels tend to rise transiently following tocilizumab therapy, before gradually declining. These post-treatment IL-6 measurements may serve as a valuable biomarker for assessing prognosis in patients undergoing this treatment. |
| format | Article |
| id | doaj-art-feb4d74f6b074d5dacdb7bf99400f20d |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-feb4d74f6b074d5dacdb7bf99400f20d2025-08-20T02:08:20ZengNature PortfolioScientific Reports2045-23222024-11-0114111110.1038/s41598-024-81028-3Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysisPanpan Liang0Yan Li1Li’e Meng2Yuting Li3Hailing Mai4Tao Li5Jiarui Ma6Junhui Ma7Jing Wang8Bing Zhuan9Wei Zhou10Department of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Anesthesiology, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityClinical Medical College, Ningxia Medical UniversityDepartment of Critical Care Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityClinical Medical College, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityDepartment of Respiratory Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical UniversityAbstract Baseline IL-6 levels have been found to be non-predictive of subsequent outcomes following tocilizumab treatment, highlighting the need for more reliable predictive markers. To address this, a retrospective analysis was conducted on the clinical profiles, diagnostic tests, and follow-up prognoses of 60 patients with severe or critical COVID-19, all of whom were identified as experiencing a cytokine storm and subsequently received tocilizumab treatment. Among the patients, the overall survival rate during follow-up was 80%, with further analysis revealing that advanced age was an independent risk factor for adverse outcomes. Following tocilizumab administration, a statistically significant increase in IL-6 and D-dimer levels was observed, while markers such as C-reactive protein (CRP), procalcitonin (PCT), and fibrinogen demonstrated reductions compared to pre-treatment values. Specifically, IL-6 levels initially surged briefly after tocilizumab intervention before gradually diminishing. To assess the prognostic utility of IL-6, the Receiver Operating Characteristic (ROC) curve was employed, which yielded an area under the curve (AUC) of 0.812, indicating strong predictive capability, with a sensitivity of 100% and a specificity of 53.49%. The optimal cut-off value for IL-6 was identified at 147.79 pg/mL. In conclusion, IL-6 levels tend to rise transiently following tocilizumab therapy, before gradually declining. These post-treatment IL-6 measurements may serve as a valuable biomarker for assessing prognosis in patients undergoing this treatment.https://doi.org/10.1038/s41598-024-81028-3COVID-19IL6TocilizumabPrognosis |
| spellingShingle | Panpan Liang Yan Li Li’e Meng Yuting Li Hailing Mai Tao Li Jiarui Ma Junhui Ma Jing Wang Bing Zhuan Wei Zhou Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis Scientific Reports COVID-19 IL6 Tocilizumab Prognosis |
| title | Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis |
| title_full | Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis |
| title_fullStr | Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis |
| title_full_unstemmed | Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis |
| title_short | Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis |
| title_sort | prognostic significance of serum interleukin 6 in severe critical covid 19 patients treated with tocilizumab a detailed observational study analysis |
| topic | COVID-19 IL6 Tocilizumab Prognosis |
| url | https://doi.org/10.1038/s41598-024-81028-3 |
| work_keys_str_mv | AT panpanliang prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT yanli prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT liemeng prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT yutingli prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT hailingmai prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT taoli prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT jiaruima prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT junhuima prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT jingwang prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT bingzhuan prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis AT weizhou prognosticsignificanceofseruminterleukin6inseverecriticalcovid19patientstreatedwithtocilizumabadetailedobservationalstudyanalysis |